Results 141 to 150 of about 9,194 (267)
The X Factor in Immunity: Sex Differences Shaped by the X Chromosome
Immunological Reviews, Volume 338, Issue 1, March 2026.ABSTRACT There are sex differences with immune responses where females exhibit stronger immune responses compared to males. Both sex hormones and sex chromosome differences between males and females contribute to the observed sex differences with innate and adaptive immune cell composition and function.
Katherine B. Radovanovic +2 more
wiley +1 more source
243PD Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) [PDF]
, 2015 Yinghao Sun +16 more
openalex +1 more source
Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study [PDF]
, 2022 Matteo Bauckneht +29 more
openalex +1 more source
Cancer, Volume 132, Issue 3, 1 February 2026.Abstract Background Germline pathogenic variants can inform targeted therapy for metastatic prostate cancer (mPC), and improve cancer early detection and risk reduction for family members. Guidelines recommend germline genetic testing be offered to all men with mPC, yet uptake of testing is only 10%–12%. Methods This prospective study enrolled veterans
Bruce Montgomery +18 more
wiley +1 more source
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 [PDF]
, 2017 Oliver Sartor +13 more
openalex +1 more source
Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer
The Prostate, Volume 86, Issue 3, Page 297-306, February 15, 2026.ABSTRACT Background Cabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration‐resistant prostate cancer (CRPC), yet it is typically reserved for post‐docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.
Taketo Kawai +13 more
wiley +1 more source
Case Reports in Clinical Practice, 2018 Radium-223 dichloride (Ra-223) is an alpha-emitting radioisotope that targets osteoblastic metastasis of prostate cancer. For Ra-223, a favorable safety profile has been described.
Yukihiro Hama, shoji koga
doaj
Clinical Transplantation, Volume 40, Issue 2, February 2026.ABSTRACT Normothermic regional perfusion (NRP) has emerged as a pivotal strategy in controlled donation after circulatory death (cDCD) liver transplantation, mitigating ischemia‐reperfusion injury and improving graft outcomes. Compared to super rapid recovery (SRR), NRP significantly reduces rates of early allograft dysfunction, primary nonfunction ...
Daisuke Imai +9 more
wiley +1 more source